Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ZVRA Zevra Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $10.97 -3.3% | $16.31 +6.3% |
| StockIQ Score | 53C- Moderate Risk: Medium | 42D Weak Risk: Medium |
| Technical | 23F | 36F |
| Fundamental | 65B- | 35F |
| Growth | 82A- | 50C- |
| Fair Value | 43D | 38F |
| News | 80A- | 50C- |
| Quality | 47D+ | 50C- |
| Risk | 62C+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Zevra Therapeutics (ZVRA) outperforms Ascentage Pharma (AAPG) in nearly every category. Its growth score of 82 is significantly higher than AAPG’s 50, and its fundamental score of 65 is also much stronger than AAPG’s 35. ZVRA’s overall rating is "Moderate," while AAPG’s is "Weak," reflecting its broader strength across metrics. The only area where AAPG scores slightly better is technical analysis, with 36 versus ZVRA’s 23.
